.png)
Xvivo Perfusion
XVIVO Perfusion – Consensus estimates Q4 2024 (Modular Finance IR Consensus)
2025-01-23 13:00
Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Number of contributors: 6 (all of which have been updated or confirmed before the report)
| KPI (MSEK, unless otherwise specified) | Q4 2024E |
| Net sales | 213 |
| Organic growth in local currency (%) | 35.6 |
| Gross profit | 162 |
| EBITDA | 47 |
| EBIT | 27 |
| Net profit | 17 |
| Earnings per share (SEK) | 0.58 |
XVIVO Perfusion’s Q4 report will be released on Tuesday, January 28, 2025 at 07.30 am CET.
support@modularfinance.com (mfn.se)
MFN - www.mfn.se